US20070238759A1 - Novel Polymorph V of Torasemide - Google Patents

Novel Polymorph V of Torasemide Download PDF

Info

Publication number
US20070238759A1
US20070238759A1 US11/763,156 US76315607A US2007238759A1 US 20070238759 A1 US20070238759 A1 US 20070238759A1 US 76315607 A US76315607 A US 76315607A US 2007238759 A1 US2007238759 A1 US 2007238759A1
Authority
US
United States
Prior art keywords
torasemide
polymorph
pharmaceutical form
form according
novel polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/763,156
Inventor
Darko Filic
Miljenko Dumic
Bozena Klepic
Aleksandar Danilovski
Marijan Tudja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutska Industrija dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutska Industrija dd filed Critical Pliva Farmaceutska Industrija dd
Priority to US11/763,156 priority Critical patent/US20070238759A1/en
Publication of US20070238759A1 publication Critical patent/US20070238759A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Definitions

  • the present invention relates to a novel crystalline form of N-(1-methylethyl aminocarbonyl)-4(3-methyl-phenylamino)-3-pyridinesulfonamide (further referred to by its generic name “torasemide”), especially to a novel polymorph V of torasemide, to a process for its preparation, to its use as a raw material for the preparation of crystalline modifications I and III of torasemide, to amorphous torasemide modifications and to pharmaceutically acceptable salts of torasemide, to pharmaceutical forms containing the said novel polymorph V of torasemide as the active ingredient as well as to its use.
  • torasemide N-(1-methylethyl aminocarbonyl)-4(3-methyl-phenylamino)-3-pyridinesulfonamide
  • Torasemide is a new potent diuretic in the class of the so-called “loop diuretics”, which is described in DE patent 25 16 025 Sample 71). Structurally, it entirely differs from diuretics of the same class such as furosemide, bumetanide and azosemide. In addition to diuretic properties it also possesses antihypertensive properties.
  • a diuretic of Henle's loop it is useful as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome, tumours, glaucoma, decreasing of intraocular pressure, acute or chronic bronchitis, in the treatment of cerebral edema caused by trauma, ischemia, concussion of the brain, metastases or epileptic attacks and in the treatment of nasal infections caused by allergens.
  • polymorphism The ability of a substance to exist in more than one crystalline form is defined as polymorphism and these different crystalline forms are named “polymorph modifications” or “polymorphs”.
  • polymorphism is caused by the ability of the molecule of a substance to change its conformation or to form different inter-molecular and intramolecular interactions, particularly hydrogen bonds, which is reflected in different atom arrangements in the crystal lattices of different polymorphs.
  • Polymorphism is found in several organic compounds. Among medicaments polymorphism is found in about 70% of barbiturates, 60% of sulfonamides and 60% of steroids, and about 50% of medicaments of the said classes are not present on the market in their most stable forms (T. Laird, Chemical Development and Scale-up in the Fine Chemical Industry, Principles and Practices, Course Manual, Scientific Update, Wyvern Cottage, 1996).
  • the different polymorphs of a substance possess different energies of the crystal lattice and, thus, they show different physical properties of the solid state such as form, density, melting point, colour, stability, dissolution rate, milling facility, granulation, compacting etc., which in medicaments may affect the possibility of the preparation of pharmaceutical forms, their stability, dissolution and bioavailability and, consequently, their action.
  • Polymorphism of medicaments is the object of studies of interdisciplinary expert teams [J. Haleblian, W. McCrone, J. Pharm. Sci. 58 (1969) 911; L. Borka, Pharm. Acta Helv. 66 (1991) 16; M. Kuhnert-Brand Toor, Pharmazie 51 (1996) 443; H. G. Brittain, J. Pharm. Sci. 86 (1997) 405; W. H. Streng, DDT 2 (1997) 415; K. Yoshii, Chem. Pharm. Bull. 45 (1997) 338, etc.].
  • a good knowledge of polymorphism represents a precondition for a critical observation of the whole process of medicament development.
  • torasemide can exist in three crystalline modifications differing with regard to the parameters of a unit cell, which is confirmed by X-ray diffraction on their monocrystals, and in one amorphous modification (HR patent application P20000162A).
  • Modification I with melting point 169° C. [ Acta Cryst . B34 (1978), 1304-1310] and modification III with melting point 165° C. (WO 00/20395) crystallize monoclinically in the space group P 2 1 /n (prisms), while modification II with melting point 162° C. crystallizes monoclinically in the space group P 2/n (foils) [ Acta Cryst . B34 (1978), 2659-2662].
  • U.S. Pat. No. 5,914,336 protected the use of a new torasemide polymorph, however, only some of its physical-chemical properties such as melting point, heat of formation, solubility, first band in IR-spectum, but no X-ray patterns of the powder and monocrystals were stated therein. Since the data as stated are not relevant for the characterization of polymorphism, the claimed subject-matter of U.S. Pat. No. 5,914,336 is not believed to be reliable.
  • novel polymorph V of torasemide is prepared according to the inventive process in the form of a flowable crystalline powder having the property of flowability, i.e. it is obtained in a “free-flow” form which is statically not chargeable.
  • DSC of the novel polymorph V of torasemide shows one exothermic maximum at about 157.59° C. (onset at about 150.74° C.) (heating rate of 10° C./min) resulting from decomposition (also evident on the basis of IR spectroscopy and thin-layer chromatography).
  • the X-ray powder pattern of the novel polymorph V of torasemide differs from the X-ray powder patterns of the known torasemide modifications ( FIG. 2 ).
  • the IR spectrum of a sample of the novel polymorph V of torasemide recorded in KBr differs from IR spectra of the known torasemide modifications.
  • the novel polymorph V of torasemide shows characteristic absorption bands at 2671 to 3327 cm ⁇ 1 and at 1468 to 1705 cm ⁇ 1 .
  • FIG. 1 represents a characteristic thermogram of differential scanning calorimetry (DSC) of the novel polymorph V of torasemide.
  • FIG. 2 represents a characteristic X-ray powder pattern of the novel polymorph V of torasemide.
  • FIG. 3 represents a characteristic IR spectrum of the novel polymorph V of torasemide recorded in KBr.
  • novel polymorph V of torasemide according to the present invention can be obtained by a rapid acidification of alkaline torasemide solutions with inorganic or organic acids.
  • a process for the preparation of the novel polymorph V of torasemide comprises:
  • a process for the preparation of the novel polymorph V of torasemide also comprises:
  • a process for the preparation of the novel polymorph V of torasemide also comprises:
  • a process for the preparation of the novel polymorph V of torasemide also comprises:
  • a process for the preparation of the novel polymorph V of torasemide also comprises:
  • a process for the preparation of the novel polymorph V of torasemide also comprises:
  • aqueous solutions of lithium hydroxide, sodium hydroxide and potassium hydroxide as well as aqueous solutions of sodium carbonate and potassium carbonate may be used for the preparation of alkaline solutions of torasemide modifications.
  • alkaline torasemide solutions may, according to the present process, be carried out with inorganic acids such as hydrochloric, sulfuric, phosphoric and nitric acids, and with organic acids such as formic, acetic, propionic, oxalic, tartaric, methanesulfonic and p-toluenesulfonic acids.
  • inorganic acids such as hydrochloric, sulfuric, phosphoric and nitric acids
  • organic acids such as formic, acetic, propionic, oxalic, tartaric, methanesulfonic and p-toluenesulfonic acids.
  • novel polymorph V of torasemide prepared according to the present process may be converted to crystalline modifications I, II or III of torasemide or to an amorphous torasemide modification according to conventional processes, i.e. it may serve as a starting material for the preparation of well-known crystalline modifications I, II or III of torasemide or an amorphous torasemide modification.
  • novel polymorph V of torasemide prepared according to the present invention may be converted into pharmaceutically acceptable salts of torasemide in a well-known manner.
  • the novel polymorph V of torasemide prepared according to the present process may be, as a suitable torasemide form, used as a diuretic or as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome, tumours, glaucoma, decreasing of intraocular pressure, acute or chronic bronchitis, in the treatment of cerebral edema caused by trauma, ischemia, concussion of the brain, metastases or epileptic attacks and in the treatment of nasal infections caused by allergens.
  • the present invention also relates to pharmaceutical forms such as tablets, capsules or injections containing an effective amount of the novel polymorph V of torasemide as an active ingredient, without or in combination with one or more pharmaceutically acceptable additives such as sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould release agents, and antiadhesive agents and, possibly, agents for regulating flowability.
  • pharmaceutically acceptable additives such as sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould release agents, and antiadhesive agents and, possibly, agents for regulating flowability.
  • the crystalline modification I of torasemide (1.0 g) prepared according to Acta Cryst . B34 (1978) 1304-1310, was dissolved in a 5% aqueous sodium hydroxide solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 5% aqueous hydrochloric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • the characteristic DSC curve of the sample as shown in FIG. 1 was recorded on the apparatus Perkin-Elmer DSC7 at a heating rate of 10° C./minute.
  • the characteristic IR spectrum of the sample as shown in FIG. 3 was recorded in KBr on the IR-spectrophotometer Nicolet-Magna 760.
  • the crystalline modification II of torasemide (1.0 g) prepared according to Acta Cryst . B34 (1978) 1304-1310, was dissolved in a 5% aqueous potassium hydroxide solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 10% aqueous acetic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the crystalline modification III of torasemide (10.0 g) prepared according to WO 00/20395, was dissolved in a 10% aqueous sodium carbonate solution (30 ml) and then at the temperature of 20° C. the solution was acidified for 60 seconds with a 5% aqueous sulfuric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (8.1 g), m.p. 153-155° C. was obtained.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the novel polymorph V of torasemide (10.0 g) according to Example 3 of the present invention was dissolved in a 5% aqueous lithium hydroxide solution (30 ml) and then at the temperature of 20° C. the solution was acidified for 120 seconds with a 5% aqueous phosphoric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (7.9 g), m.p. 153-155° C. was obtained.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • the novel polymorph V of torasemide obtained according to Example 1 of the present invention was subjected to testing the release of the active substance in water at the temperature of 37° C. (USP 24) and the results are given in Table 1.
  • TABLE 1 Release of the novel polymorph V of torasemide in water (USP 24) (37° C., 50 rpm, 1000 ml) Time Released torasemide (min) (%) 0 0 15 11.3 30 20.5 45 26.0 60 30.0 90 36.0 120 40.7

Abstract

The invention relates to a novel polymorph V of torasemide, to a process for its preparation, to its use as a raw material for the preparation of crystalline modifications I and III of torasemide, to amorphous torasemide modifications and to pharmaceutically acceptable salts of torasemide, to pharmaceutical forms containing the said novel polymorph V of torasemide as the active ingredient as well as to its use.

Description

  • The present invention relates to a novel crystalline form of N-(1-methylethyl aminocarbonyl)-4(3-methyl-phenylamino)-3-pyridinesulfonamide (further referred to by its generic name “torasemide”), especially to a novel polymorph V of torasemide, to a process for its preparation, to its use as a raw material for the preparation of crystalline modifications I and III of torasemide, to amorphous torasemide modifications and to pharmaceutically acceptable salts of torasemide, to pharmaceutical forms containing the said novel polymorph V of torasemide as the active ingredient as well as to its use.
  • Torasemide is a new potent diuretic in the class of the so-called “loop diuretics”, which is described in DE patent 25 16 025 Sample 71). Structurally, it entirely differs from diuretics of the same class such as furosemide, bumetanide and azosemide. In addition to diuretic properties it also possesses antihypertensive properties.
  • As a diuretic of Henle's loop it is useful as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome, tumours, glaucoma, decreasing of intraocular pressure, acute or chronic bronchitis, in the treatment of cerebral edema caused by trauma, ischemia, concussion of the brain, metastases or epileptic attacks and in the treatment of nasal infections caused by allergens.
  • The ability of a substance to exist in more than one crystalline form is defined as polymorphism and these different crystalline forms are named “polymorph modifications” or “polymorphs”. In general, polymorphism is caused by the ability of the molecule of a substance to change its conformation or to form different inter-molecular and intramolecular interactions, particularly hydrogen bonds, which is reflected in different atom arrangements in the crystal lattices of different polymorphs. Polymorphism is found in several organic compounds. Among medicaments polymorphism is found in about 70% of barbiturates, 60% of sulfonamides and 60% of steroids, and about 50% of medicaments of the said classes are not present on the market in their most stable forms (T. Laird, Chemical Development and Scale-up in the Fine Chemical Industry, Principles and Practices, Course Manual, Scientific Update, Wyvern Cottage, 1996).
  • The different polymorphs of a substance possess different energies of the crystal lattice and, thus, they show different physical properties of the solid state such as form, density, melting point, colour, stability, dissolution rate, milling facility, granulation, compacting etc., which in medicaments may affect the possibility of the preparation of pharmaceutical forms, their stability, dissolution and bioavailability and, consequently, their action.
  • Polymorphism of medicaments is the object of studies of interdisciplinary expert teams [J. Haleblian, W. McCrone, J. Pharm. Sci. 58 (1969) 911; L. Borka, Pharm. Acta Helv. 66 (1991) 16; M. Kuhnert-Brandstätter, Pharmazie 51 (1996) 443; H. G. Brittain, J. Pharm. Sci. 86 (1997) 405; W. H. Streng, DDT 2 (1997) 415; K. Yoshii, Chem. Pharm. Bull. 45 (1997) 338, etc.]. A good knowledge of polymorphism represents a precondition for a critical observation of the whole process of medicament development. Thus, at deciding on the production of a pharmaceutical form in solid state and with regard to the dose size, stability, dissolution and anticipated action, it is necessary to determine the existence of all solid state forms (on the market some computer programmes can be found, e.g.
    Figure US20070238759A1-20071011-P00900
    Polymorph
    Figure US20070238759A1-20071011-P00901
    as a module of
    Figure US20070238759A1-20071011-P00900
    Cerius2
    Figure US20070238759A1-20071011-P00901
    programme, MSI Inc., USA) and to determine the physical-chemical properties of each of them. Only on the basis of these determinations the appropriate polymorph can be selected for the development of pharmaceutical formulations of desired properties.
  • From the great number of such efforts only a few will be mentioned as an example. Thus, Gordon et al. (U.S. Pat. No. 4,476,248) protected a novel crystalline form of ibuprofen and a process for the preparation thereof. Bunnel et al. (EP 733,635) protected a novel crystalline form, a process for the preparation thereof and pharmaceutical formulations of the drug olanzapine containing the said novel form. R. B. Gandhi et al. (EP 749,969) protected a novel process for the preparation of a polymorphous form I of stavudine from a mixture of one or more forms I, II and III, whereas A. Caron et al. (EP 708,103) protected a novel crystalline form of irbesartane, a process for the preparation thereof as well as pharmaceutical formulations containing this crystalline form. Chikaraishi et al. (WO 9626197) protected, in addition to a polymorphous form, also an amorphous form of piretanide as well as processes for the preparation thereof. J.-B. Cha et al. (WO 9857967) protected an amorphous form, a process for the preparation thereof and pharmaceutical formulations of the medicament itraconazole containing this amorphous form, whereas E. Occeli et al. (WO 90/00553) protected crystal polymorphs I and II and amorphs of the medicament rifapentine hydrochloride and hydrobromide. Further, for the new antidiabetic troglitazone G. Om Reddy et al. (U.S. Pat. No. 5,700,820) protected six polymorphs: five crystal polymorphs and one amorphous one.
  • It is known that torasemide can exist in three crystalline modifications differing with regard to the parameters of a unit cell, which is confirmed by X-ray diffraction on their monocrystals, and in one amorphous modification (HR patent application P20000162A). Modification I with melting point 169° C. [Acta Cryst. B34 (1978), 1304-1310] and modification III with melting point 165° C. (WO 00/20395) crystallize monoclinically in the space group P 21/n (prisms), while modification II with melting point 162° C. crystallizes monoclinically in the space group P 2/n (foils) [Acta Cryst. B34 (1978), 2659-2662].
  • In addition to the above, U.S. Pat. No. 5,914,336 protected the use of a new torasemide polymorph, however, only some of its physical-chemical properties such as melting point, heat of formation, solubility, first band in IR-spectum, but no X-ray patterns of the powder and monocrystals were stated therein. Since the data as stated are not relevant for the characterization of polymorphism, the claimed subject-matter of U.S. Pat. No. 5,914,336 is not believed to be reliable.
  • In our further research in the field of torasemide we have surprisingly found a novel crystalline torasemide modification, i.e. a novel polymorph V of torasemide which has hitherto not been known.
  • The novel polymorph V of torasemide is prepared according to the inventive process in the form of a flowable crystalline powder having the property of flowability, i.e. it is obtained in a “free-flow” form which is statically not chargeable.
  • In a solution the novel polymorph V of torasemide is identical to other known torasemide modifications, which is evident from NMR and UV spectra. On the other hand, solid state analysis techniques such as differential scanning calorimetry (DSC), X-ray powder pattern (XRD) and IR spectroscopy reveal a difference in comparison to the known torasemide modifications.
  • DSC of the novel polymorph V of torasemide (FIG. 1) shows one exothermic maximum at about 157.59° C. (onset at about 150.74° C.) (heating rate of 10° C./min) resulting from decomposition (also evident on the basis of IR spectroscopy and thin-layer chromatography).
  • The X-ray powder pattern of the novel polymorph V of torasemide differs from the X-ray powder patterns of the known torasemide modifications (FIG. 2).
  • The IR spectrum of a sample of the novel polymorph V of torasemide recorded in KBr (FIG. 3) differs from IR spectra of the known torasemide modifications. The novel polymorph V of torasemide shows characteristic absorption bands at 2671 to 3327 cm−1 and at 1468 to 1705 cm−1.
  • FIG. 1 represents a characteristic thermogram of differential scanning calorimetry (DSC) of the novel polymorph V of torasemide.
  • FIG. 2 represents a characteristic X-ray powder pattern of the novel polymorph V of torasemide.
  • FIG. 3 represents a characteristic IR spectrum of the novel polymorph V of torasemide recorded in KBr.
  • The novel polymorph V of torasemide according to the present invention can be obtained by a rapid acidification of alkaline torasemide solutions with inorganic or organic acids.
  • A process for the preparation of the novel polymorph V of torasemide comprises:
    • (i) the preparation of a polymorph I of torasemide according to a known process,
    • (ii) the dissolution of the polymorph I of torasemide in an aqueous solution of a base,
    • (iii) the filtration of the obtained solution,
    • (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0° C. and 35° C.,
    • (v) the filtration of the obtained suspension,
    • (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50° C., the obtained crystals being characterized by the following data:
      • DSC: exothermic maximum at about 157.59° C. (onset at about 150.74° C.) (FIG. 1);
      • X-ray powder pattern (2Θ): 5.610; 6.130; 7.480; 7.970; 9.310; 9.615; 10.835; 11.020; 12.340; 13.075; 13.460; 13.920; 14.200; 15.090; 16.080; 16.710; 17.445; 17.720; 18.460; 18.850; 19.825; 20.340; 20.990; 21.980; 22.075; 22.630; 22.935; 23.410; 23.845; 24.880; 25.560; 26.035; 27.285; 27.540; 28.170; 28.645; 29.350; 29.975; 30.575; 31.265; 32.300; 34.050; 35.650; 36.375; 37.100, and 38.145 (FIG. 2);
      • IR-characteristic absorption bands (cm−1): at 2671 to 3327 and at 1468 to 1705 (FIG. 3).
  • According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:
    • (i) the preparation of a polymorph II of torasemide according to a known process,
    • (ii) the dissolution of the polymorph II of torasemide in an aqueous solution of a base,
    • (iii) the filtration of the obtained solution,
    • (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0° C. and 35° C.,
    • (v) the filtration of the obtained suspension,
    • (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50° C., the obtained crystals being characterized by the data represented in the previous process.
  • According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:
    • (i) the preparation of a polymorph III of torasemide according to a known process,
    • (ii) the dissolution of the polymorph III of torasemide in an aqueous solution of a base,
    • (iii) the filtration of the obtained solution,
    • (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0° C. and 35° C.,
    • (v) the filtration of the obtained suspension,
    • (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50° C., the obtained crystals being characterized by the data represented in the previous process.
  • According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:
    • (i) the preparation of an amorphous torasemide modification according to a known process,
    • (ii) the dissolution of the amorphous torasemide modification in an aqueous solution of a base,
    • (iii) the filtration of the obtained solution,
    • (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0° C. and 35° C.,
    • (v) the filtration of the obtained suspension,
    • (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50° C., the obtained crystals being characterized by the data represented in the previous process.
  • According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:
    • (i) the preparation of a novel polymorph V of torasemide according to the process of the present invention,
    • (ii) the dissolution of the novel polymorph V of torasemide in an aqueous solution of a base,
    • (iii) the filtration of the obtained solution,
    • (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0° C. and 35° C.,
    • (v) the filtration of the obtained suspension,
    • (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50° C., the obtained crystals being characterized by the data represented in the previous process.
  • According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:
    • (i) the preparation of polymorphs I, II and III of torasemide according to known processes, the preparation of an amorphous torasemide modification according to a known process and the preparation of the novel polymorph V of torasemide according to the process of the present invention,
    • (ii) the dissolution of any mixture of the polymorphs I, II and III of torasemide, of the amorphous torasemide modification or the novel polymorph V of torasemide in an aqueous solution of a base,
    • (iii) the filtration of the obtained solution,
    • (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0° C. and 35° C.,
    • (v) the filtration of the obtained suspension,
    • (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50° C., the obtained crystals being characterized by the data represented in the previous process.
  • According to the present process, aqueous solutions of lithium hydroxide, sodium hydroxide and potassium hydroxide as well as aqueous solutions of sodium carbonate and potassium carbonate may be used for the preparation of alkaline solutions of torasemide modifications.
  • The acidification of alkaline torasemide solutions may, according to the present process, be carried out with inorganic acids such as hydrochloric, sulfuric, phosphoric and nitric acids, and with organic acids such as formic, acetic, propionic, oxalic, tartaric, methanesulfonic and p-toluenesulfonic acids.
  • It has also been established that at using the present process no decomposition of torasemide takes place, i.e. a chemically pure novel polymorph V of torasemide (TLC and HPLC) is obtained.
  • It has been additionally established that under normal storage conditions the novel polymorph V of torasemide is stable at milling and pressing, i.e. it is not transformed into crystalline modifications I, II and III of torasemide or into an amorphous torasemide modification.
  • The novel polymorph V of torasemide prepared according to the present process may be converted to crystalline modifications I, II or III of torasemide or to an amorphous torasemide modification according to conventional processes, i.e. it may serve as a starting material for the preparation of well-known crystalline modifications I, II or III of torasemide or an amorphous torasemide modification.
  • The novel polymorph V of torasemide prepared according to the present invention may be converted into pharmaceutically acceptable salts of torasemide in a well-known manner.
  • The examination of the release (USP 24) of the novel polymorph V of torasemide in water in comparison with the release profile of known crystalline torasemide modifications in the same medium revealed a slower release thereof. This makes the novel polymorph V of torasemide suitable for the preparation of pharmaceutical preparations having immediate or prolonged action.
  • The novel polymorph V of torasemide prepared according to the present process may be, as a suitable torasemide form, used as a diuretic or as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome, tumours, glaucoma, decreasing of intraocular pressure, acute or chronic bronchitis, in the treatment of cerebral edema caused by trauma, ischemia, concussion of the brain, metastases or epileptic attacks and in the treatment of nasal infections caused by allergens.
  • The present invention also relates to pharmaceutical forms such as tablets, capsules or injections containing an effective amount of the novel polymorph V of torasemide as an active ingredient, without or in combination with one or more pharmaceutically acceptable additives such as sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould release agents, and antiadhesive agents and, possibly, agents for regulating flowability.
  • The present invention is illustrated by the following non-limiting Examples.
  • EXAMPLE 1
  • The crystalline modification I of torasemide (1.0 g) prepared according to Acta Cryst. B34 (1978) 1304-1310, was dissolved in a 5% aqueous sodium hydroxide solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 5% aqueous hydrochloric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • The characteristic DSC curve of the sample as shown in FIG. 1 was recorded on the apparatus Perkin-Elmer DSC7 at a heating rate of 10° C./minute.
  • The characteristic X-ray powder pattern as shown in FIG. 2 was recorded on the instrument PHILIPS PW3710 under Cu X-rays [λ(CuKα1)=1.54046 Å and λ(CuKα2)=1.54439 Å].
  • The characteristic IR spectrum of the sample as shown in FIG. 3 was recorded in KBr on the IR-spectrophotometer Nicolet-Magna 760.
  • EXAMPLE 2
  • The crystalline modification II of torasemide (1.0 g) prepared according to Acta Cryst. B34 (1978) 1304-1310, was dissolved in a 5% aqueous potassium hydroxide solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 10% aqueous acetic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 3
  • The crystalline modification III of torasemide (10.0 g) prepared according to WO 00/20395, was dissolved in a 10% aqueous sodium carbonate solution (30 ml) and then at the temperature of 20° C. the solution was acidified for 60 seconds with a 5% aqueous sulfuric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (8.1 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 4
  • The amorphous torasemide modification (10.0 g) prepared according to HR patent application P20000162A, was dissolved in a 10% aqueous potassium carbonate solution (30 ml) and then at the temperature of 20° C. the solution was acidified for 90 seconds with a 10% aqueous tartaric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (8.0 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 5
  • The novel polymorph V of torasemide (10.0 g) according to Example 3 of the present invention was dissolved in a 5% aqueous lithium hydroxide solution (30 ml) and then at the temperature of 20° C. the solution was acidified for 120 seconds with a 5% aqueous phosphoric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (7.9 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 6
  • A mixture (1.0 g) of crystalline modifications I and II of torasemide prepared according to Acta Cryst. B34 (1978) 1304-1310, was dissolved in a 10% aqueous sodium carbonate solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 5% aqueous p-toluenesulfonic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 7
  • A mixture (1.0 g) of crystalline modifications I and III of torasemide prepared according to Acta Cryst. B34 (1978) 1304-1310 and WO 00/20395, was dissolved in a 5% aqueous sodium hydroxide solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 5% aqueous nitric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 8
  • A mixture (1.0 g) of crystalline modifications II and III of torasemide prepared according to Acta Cryst. B34 (1978) 1304-1310 and WO 00/20395, was dissolved in a 5% aqueous potassium hydroxide solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 10% aqueous propionic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 9
  • A mixture (1.0 g) of crystalline modifications I, II and III of torasemide prepared according to Acta Cryst. B34 (1978) 1304-1310 and WO 00/20395, was dissolved in a 5% aqueous lithium hydroxide solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 10% aqueous oxalic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 10
  • A mixture (1.0 g) of a crystalline modification I of torasemide and an amorphous torasemide modification prepared according to Acta Cryst. B34 (1978) 1304-1310 and HR patent application P20000162A, was dissolved in a 10% aqueous sodium carbonate solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 5% aqueous methanesulfonic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 11
  • A mixture (1.0 g) of a crystalline modification I of torasemide and of the novel polymorph V of torasemide prepared according to Acta Cryst. B34 (1978) 1304-1310 and according to Example 1 of the present invention, was dissolved in a 10% aqueous potassium carbonate solution (3 ml) and then at the temperature of 20° C. the solution was acidified for 15 seconds with a 5% aqueous hydrochloric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 12
  • A mixture (10.0 g) of crystalline modifications I, II and III of torasemide, of an amorphous torasemide modification and of the novel polymorph V of torasemide prepared according to Acta Cryst. B34 (1978) 1304-13 10, WO 00/20395, HR patent application P20000162A and Example 1 of the present invention, was dissolved in a 5% aqueous sodium hydroxide solution (30 ml) and then at the temperature of 20° C. the solution was acidified for 60 seconds with a 10% aqueous acetic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50° C. A chemically pure novel polymorph V of torasemide (8.0 g), m.p. 153-155° C. was obtained.
  • The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.
  • EXAMPLE 13
  • The novel polymorph V of torasemide obtained according to Example 1 of the present invention was subjected to testing the release of the active substance in water at the temperature of 37° C. (USP 24) and the results are given in Table 1.
    TABLE 1
    Release of the novel polymorph V of torasemide in
    water (USP 24) (37° C., 50 rpm, 1000 ml)
    Time Released torasemide
    (min) (%)
    0 0
    15 11.3
    30 20.5
    45 26.0
    60 30.0
    90 36.0
    120 40.7

Claims (17)

1-8. (canceled)
9. A process for the preparation of the crystalline modifications I, II and III torasemide or of an amorphous torasemide modification which comprises using as a raw material a polymorph V of torasemide characterized by the following data:
DSC: exothermic maximum at about 157.59° C. (onset at about 150.74° C.) with the heating rate of 10° C./min;
X-ray powder pattern (2Θ) : 5.610; 6.130; 7.480; 7.970; 9.310; 9.615; 10.835; 11.020; 12.340; 13.075; 13.460; 13.920; 14.200; 15.090; 16.080; 16.710; 17.445; 17.720; 18.460; 18.850; 19.825; 20.340; 20.990; 21.980; 22.075; 22.630; 22.935; 23.410; 23.845; 24.880; 25.560; 26.035; 27.285; 27.540; 28.170; 28.645; 29.350; 29.975; 30.575; 31.265; 32.300; 34.050; 35.650; 36.375; 37.100 and 38.145;
IR-characteristic absorption bands at 2671 to 3327 and at 1468 to 1705cm−1.
10. A process for the preparation of pharmaceutically acceptable salts of torasemide which comprises using a polymorph V of torasemide characterized by the following data:
DSC: exothermic maximum at about 157.59° C. (onset at about 150.74° C.) with the heating rate of 10° C./min;
X-ray powder pattern (2Θ): 5.610; 6.130; 7.480; 7.970; 9.310; 9.615; 10.835; 11.020; 12.340; 13.075; 13.460; 13.920; 14.200; 15.090; 16.080; 16.710; 17.445; 17.720; 18.460; 18.850; 19.825; 20.340; 20.990; 21.980; 22.075; 22.630; 22.935; 23.410; 23.845; 24.880; 25.560; 26.035; 27.285; 27.540; 28.170; 28.645; 29.350; 29.975; 30.575; 31.265; 32.300; 34.050; 35.650; 36.375; 37.100 and 38.145;
IR-characteristic absorption bands at 2671 to 3327 and at 1468 to 1705 cm−1.
11. (canceled)
12. Pharmaceutical form, characterized in that as an active ingredient it contains an effective amount of a polymorph V of torasemide characterized by the following data:
DSC: exothermic maximum at about 157.59° C. (onset at about 150.74° C.) with the heating rate of 10° C./min;
X-ray powder pattern (2Θ): 5.610; 6.130; 7.480; 7.970; 9.310; 9.615; 10.835; 11.020; 12.340; 13.075; 13.460; 13.920; 14.200; 15.090; 16.080; 16.710; 17.445; 17.720; 18.460; 18.850; 19.825; 20.340; 20.990; 21.980; 22.075; 22.630; 22.935; 23.410; 23.845; 24.880; 25.560; 26.035; 27.285; 27.540; 28.170; 28.645; 29.350; 29.975; 30.575; 31.265; 32.300; 34.050; 35.650; 36.375; 37.100 and 38.145;
IR-characteristic absorption bands at 2671 to 3327 and at 1468 to 1705 cm−1, without or in combination with one or more pharmaceutically acceptable additives.
13. Pharmaceutical form according to claim 12, characterized in that it is a tablet, a capsule or an injection.
14. A method of treatment selected from the group consisting of treating a patient in need of a diuretic; a patient suffering from
heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia; and
patient suffering from a treating a cenaitium selected from the group consisting of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome, tumors, glaucoma, decreasing of intraocular pressure, acute or chronic bronchitis, cerebral edema caused by trauma, ischemia, concussion of the brain, metastases or epileptic attacks, and nasal infections caused by allergens;
by administering to said patient an effecture amount of a polymorph V of torasemide characterized by the following data:
DSC: exothermic maximum at about 157.59° C. (onset at about 150.74° C.) with the heating rate of 10° C./min;
X-ray powder pattern (2Θ) : 5.610; 6.130; 7.480; 7.970; 9.310; 9.615; 10.835; 11.020; 12.340; 13.075; 13.460; 13.920; 14.200; 15.090; 16.080; 16.710; 17.445; 17.720; 18.460; 18.850; 19.825; 20.340; 20.990; 21.980; 22.075; 22.630; 22.935; 23.410; 23.845; 24.880; 25.560; 26.035; 27.285; 27.540; 28.170; 28.645; 29.350; 29.975; 30.575; 31.265; 32.300; 34.050; 35.650; 36.375; 37.100, and 38.145;
IR-characteristic absorption bands at 2671 to 3327 and at 1468 to 1705 cm−1.
15. Pharmaceutical form according to claim 12 wherein said pharmaceutically acceptable additives are selected from the group consisting of sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould release agents, antiadhesive agents and agents for regulating flowability.
16. Pharmaceutical form according to claim 12 wherein said polymorph V of torasemide is chemically pure.
17. Pharmaceutical form according to claim 12 wherein said polymorph V of torasemide contains no water.
18. Pharmaceutical form according to claim 12 wherein said polymorph V of torasemide contains no solvent.
19. Pharmaceutical form according to claim 15 wherein said polymorph V of torasemide is chemically pure.
20. Pharmaceutical form according to claim 15 wherein said polymorph V of torasemide contains no water.
21 Pharmaceutical form according to claim 15 wherein said polymorph V of torasemide contains no solvent.
22. The method according to claim 14 wherein said polymorph V of torasemide contains no water.
23. The method according to claim 14 wherein said polymorph V of torasemide contains no solvent.
24. The method according to claim 14 polymorph V of torasemide is chemically pure.
US11/763,156 2000-05-19 2007-06-14 Novel Polymorph V of Torasemide Abandoned US20070238759A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/763,156 US20070238759A1 (en) 2000-05-19 2007-06-14 Novel Polymorph V of Torasemide

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
HR20000328A HRP20000328A2 (en) 2000-05-19 2000-05-19 Novel polymorph v of torasemide
HRP20000328A 2000-05-19
PCT/HR2000/000033 WO2001087841A1 (en) 2000-05-19 2000-09-25 Novel polymorph v of torasemide
US27688103A 2003-06-11 2003-06-11
US11/763,156 US20070238759A1 (en) 2000-05-19 2007-06-14 Novel Polymorph V of Torasemide

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/HR2000/000033 Division WO2001087841A1 (en) 2000-05-19 2000-09-25 Novel polymorph v of torasemide
US27688103A Division 2000-05-19 2003-06-11

Publications (1)

Publication Number Publication Date
US20070238759A1 true US20070238759A1 (en) 2007-10-11

Family

ID=10947111

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/276,881 Expired - Fee Related US7241782B1 (en) 2000-05-19 2000-09-25 Polymorph V of torasemide
US11/763,156 Abandoned US20070238759A1 (en) 2000-05-19 2007-06-14 Novel Polymorph V of Torasemide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/276,881 Expired - Fee Related US7241782B1 (en) 2000-05-19 2000-09-25 Polymorph V of torasemide

Country Status (32)

Country Link
US (2) US7241782B1 (en)
EP (1) EP1283828B1 (en)
JP (1) JP2003533512A (en)
KR (1) KR20030016267A (en)
CN (1) CN1520403A (en)
AP (1) AP2002002679A0 (en)
AR (1) AR028840A1 (en)
AT (1) ATE342890T1 (en)
AU (1) AU2000274381A1 (en)
BG (1) BG107407A (en)
BR (1) BR0015877A (en)
CA (1) CA2409699A1 (en)
CZ (1) CZ20024104A3 (en)
DE (1) DE60031450T2 (en)
DZ (1) DZ3356A1 (en)
EA (1) EA005003B1 (en)
EE (1) EE200200637A (en)
GE (1) GEP20043321B (en)
HR (1) HRP20000328A2 (en)
HU (1) HUP0302135A2 (en)
IL (1) IL152810A0 (en)
IS (1) IS6620A (en)
MA (1) MA25748A1 (en)
MX (1) MXPA02011402A (en)
NO (1) NO20025509D0 (en)
NZ (1) NZ522544A (en)
PL (1) PL358257A1 (en)
SK (1) SK17712002A3 (en)
TR (1) TR200202544T2 (en)
WO (1) WO2001087841A1 (en)
YU (1) YU84202A (en)
ZA (1) ZA200209181B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158949A1 (en) * 2003-09-04 2005-07-21 Manning Homer M. Semiconductor devices

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781461C (en) * 1999-08-11 2006-02-23 Teva Pharmaceutical Industries Ltd. Torsemide polymorphs
IN192178B (en) 2001-08-03 2004-03-06 Ranbaxy Lab
CN1824647B (en) * 2005-02-22 2011-04-20 田边三菱制药株式会社 Crystal of (+-)2-(dimethylamino)-1-{[o-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride
CN100421662C (en) * 2005-11-08 2008-10-01 周卓和 Disperese torasemide tablet and its prepn and application
CN104370805B (en) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 Torasemide compound
CN105949115A (en) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 Novel crystal form torasemide
CN115417810B (en) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 Refining method of torsemide crystal form I
CN117486789A (en) * 2023-12-29 2024-02-02 江西中医药大学 Torase Mi Gongjing salt and preparation method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018929A (en) * 1974-04-17 1977-04-19 A. Christiaens Societe Anonyme 3-Loweralkylcarbamylsulfonamido-4-phenylaminopyridine-N-oxides, derivatives thereof and pharmaceutical compositions containing same
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US5700820A (en) * 1996-02-20 1997-12-23 Dr. Reddy's Research Foundation Polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6399637B1 (en) * 1998-02-10 2002-06-04 Pliva, Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija, Dionicko Drustvo Crystal modification of torasemide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018929A (en) * 1974-04-17 1977-04-19 A. Christiaens Societe Anonyme 3-Loweralkylcarbamylsulfonamido-4-phenylaminopyridine-N-oxides, derivatives thereof and pharmaceutical compositions containing same
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
USRE30633E (en) * 1974-04-17 1981-06-02 A. Christiaens Societe Anonyme 3-Lower alkylcarbamylsulfonamido-4-phenylaminopyridines, n-oxides, derivatives thereof and pharmaceutical compositions containing same
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US5700820A (en) * 1996-02-20 1997-12-23 Dr. Reddy's Research Foundation Polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
US6399637B1 (en) * 1998-02-10 2002-06-04 Pliva, Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija, Dionicko Drustvo Crystal modification of torasemide
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158949A1 (en) * 2003-09-04 2005-07-21 Manning Homer M. Semiconductor devices

Also Published As

Publication number Publication date
ZA200209181B (en) 2004-02-12
ATE342890T1 (en) 2006-11-15
CA2409699A1 (en) 2001-11-22
NO20025509L (en) 2002-11-15
KR20030016267A (en) 2003-02-26
BG107407A (en) 2004-01-30
EE200200637A (en) 2004-04-15
SK17712002A3 (en) 2003-05-02
EA200201236A1 (en) 2003-04-24
IS6620A (en) 2002-11-14
EP1283828A1 (en) 2003-02-19
TR200202544T2 (en) 2003-03-21
YU84202A (en) 2006-05-25
NZ522544A (en) 2004-07-30
JP2003533512A (en) 2003-11-11
CN1520403A (en) 2004-08-11
GEP20043321B (en) 2004-04-13
IL152810A0 (en) 2003-06-24
DZ3356A1 (en) 2001-11-22
DE60031450T2 (en) 2007-09-20
EP1283828B1 (en) 2006-10-18
BR0015877A (en) 2003-04-29
US7241782B1 (en) 2007-07-10
DE60031450D1 (en) 2006-11-30
PL358257A1 (en) 2004-08-09
HRP20000328A2 (en) 2002-02-28
NO20025509D0 (en) 2002-11-15
AR028840A1 (en) 2003-05-28
EA005003B1 (en) 2004-10-28
MXPA02011402A (en) 2003-06-06
WO2001087841A1 (en) 2001-11-22
AU2000274381A1 (en) 2001-11-26
MA25748A1 (en) 2003-04-01
AP2002002679A0 (en) 2002-12-31
CZ20024104A3 (en) 2003-04-16
HUP0302135A2 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
US20070238759A1 (en) Novel Polymorph V of Torasemide
US20060205951A1 (en) New crystal modification of torasemide
US6767917B1 (en) Amorphous torasemide modification
NO803911L (en) 3-ACYLAMINO-5- (PYRIDINYL) -2 (1H) -PYRIDINONES AND PROCEDURES FOR PREPARING THEREOF
MXPA01003325A (en) New crystal modification iii of torasemide

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION